XSHE
002900
Market cap443mUSD
Jul 10, Last price
9.80CNY
1D
3.05%
1Q
-19.41%
IPO
-48.64%
Name
Harbin Medisan Pharmaceutical Co Ltd
Chart & Performance
P/E
—
P/S
3.93
EPS
—
Div Yield, %
2.10%
Shrs. gr., 5y
0.44%
Rev. gr., 5y
-3.55%
Revenues
789m
-30.29%
Net income
-340m
L
CFO
-36m
L
Dividend
May 29, 20250.2 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1996 and based in Harbin, China, Harbin Medisan Pharmaceutical Co., Ltd. specializes in the full lifecycle of chemical pharmaceutical products within China, from research and development to manufacturing and sales. The company's comprehensive product line includes both active pharmaceutical ingredients (APIs) and various finished drug forms. Its offerings address a wide array of medical conditions, encompassing treatments for neurological, cardiovascular, and musculoskeletal systems, systemic infections, nutritional support, fluid balance, and other general healthcare needs.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑00 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||